# Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/osimertinib-as-neoadjuvant-therapy-in-patients-with-egfr-mutant-resectable-stage/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Chao Lv,Wentao Fang,Nan Wu,Wenjie Jiao,Shidong Xu,Haitao Ma,Jia Wang,Rui Wang,Chunyu Ji,Shaolei Li,Yuzhao Wang,Yan Shi,Fangliang Lu,Yuquan Pei,Yinan Liu,Yue Yang |
| Citations | 115 |
| DOI | 10.1016/j.lungcan.2023.02.011 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | http://www.lungcancerjournal.info/article/S0169500223000727/pdf |
| OpenAlex ID | https://openalex.org/W4321202935 |
| PMID | 36863124 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Yinan Liu](https://scholariq.org/researchers/yinan-liu/)

## Paper journal

- [Lung Cancer](https://scholariq.org/journals/lung-cancer/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.